DHL Supply Chain to invest $400 million to grow its US pharma, medical device distribution network
Leading North American contract logistics player DHL Supply Chain within Deutsche Post DHL Group, recently announced that it's Life Sciences and Healthcare (LSHC) sector is investing upwards of $400 million to expand its pharmaceutical and medical device distribution network footprint by 27 percent this year – which is nearly 3 million additional square feet.
With the ultimate goal of bringing critical healthcare products closer to trade partners and patients, DHL Supply Chain's new investment includes six new U.S. sites by the end of 2022. The investment includes costs to invest in new buildings and technology, as well as the fit-out and start-up of new or expanded operations.
"This latest investment in our Life Sciences and Healthcare sector is testament to our track record and pedigree for delivering unrivaled supply chain expertise to our partners," said Jim Saponaro, President, Life Sciences & Healthcare, DHL Supply Chain North America. "This substantial expansion will only further deepen the connections between our customers and the patients they serve by providing best-in-class end-to-end supply chain solutions."
The expansion will grow the list of DHL Supply Chain's LSHC sites to 34 by the end of 2022, strategically located across the U.S. including; Atlanta, GA, Cincinnati, OH, Memphis, TN, Reno, NV, and Lebanon, PA. The new builds will be fully licensed with temperature-controlled space that supports pharmaceutical storage requirements. A press release from the company cited that the sites will also allow integrated solutions for both packaging and managed transportation.
DHL Supply Chain has many services in the life sciences and healthcare sector, including warehousing, secondary packaging, managed transportation, and end-to-end supply chain management services and it also happens to be the fastest growing sector at DHL Supply Chain, as per the release.
